Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | PLK1 | P53350 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919709 | 0.85 | MAPT (0.57) | GAAPLK1NPC1MAPTALDH1A1 | |
| SCHEMBL12966676 | 0.85 | PLK1 (0.47) | PLK1NPC1MAPTL3MBTL1CYP3A4 | |
| SCHEMBL12966671 | 0.83 | NPC1 (0.54) | PLK1NPC1MAPTALDH1A1MEN1 | |
| SCHEMBL24386375 | 0.82 | GAA (0.49) | GAANR1I2NPC1MAPTALDH1A1 | |
| SCHEMBL7919711 | 0.81 | NPC1 (0.52) | PLK1NPC1MAPTMMP1MEN1 | |
| SCHEMBL7915808 | 0.81 | PLK1 (0.67) | PLK1NPC1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL20424310 | 0.81 | GAA (0.59) | GAAPLK1NR1I2NPC1MAPT | |
| SCHEMBL7906086 | 0.80 | PLK1 (0.54) | GAAPLK1NPC1MAPTALDH1A1 | |
| SCHEMBL4751615 | 0.79 | PLK1 (0.75) | GAAPLK1NR1I2NPC1MAPT | |
| SCHEMBL5180990 | 0.78 | MAPT (0.64) | GAANPC1MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2010048340-A2 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, DNPEP, ALG8 | GAA 163/4885PLK1 3708/4885NR1I2 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.